2026-04-17T02:35:07Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2244622026-04-07T20:41:28Zcom_2072_1057col_2072_478916col_2072_478917

urn:hdl:2445/224462 Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition Smith-Byrne, Karl Fensom, Georgina K. Noor, Urwah Watts, Eleanor L. Allen, Naomi E. Amiano, Pilar Chirlaque, María Dolores Crous Bou, Marta Guevara Eslava, Marcela Palli, Domenico Katzke, Verena Sacerdote, Carlotta Sánchez Pérez, María José Schulze, Matthias B. Sieri, Sabina Tumino, Rosario Tsilidis, Konstantinos K. Kaaks, Rudolf Gunter, Marc J. Riboli, Elio Key, Timothy J. Travis, Ruth C. Càncer de pròstata Antigen específic de la pròstata Prostate cancer Prostate-specific antigen Background: PSA is central to referrals for prostate biopsy but has low specificity for aggressive prostate cancer. This study evaluates the 4Kscore (OPKO Diagnostics) versus total PSA in predicting short- and long-term risks of aggressive prostate cancer. Methods: Baseline blood samples from 1,658 men diagnosed with prostate cancer (median diagnosis time = 8.6 years) and 1,658 matched controls in the European Prospective Investigation into Cancer and Nutrition were analyzed. Discrimination for the 4Kscore and total PSA was assessed using the AUC with 95% confidence intervals (CI) via bootstrapping. Results: For high-grade tumors, AUCs were 0.69 (95% CI, 0.66-0.72) for the 4Kscore and 0.75 (95% CI, 0.73-0.78) for total PSA. For advanced-stage disease, AUCs were 0.71 (95% CI, 0.66-0.75) for the 4Kscore and 0.77 (95% CI, 0.73-0.80) for total PSA. Similar findings were observed for other aggressive cancer endpoints. Among men with PSA >2 ng/mL, the 4Kscore had better discrimination than PSA for overall prostate cancer, high-grade disease, and prostate cancer death but only in men <60 years at recruitment. Conclusions: In this large European study, the 4Kscore did not significantly improve the prediction of clinically significant prostate cancer compared with total PSA, except in younger men with elevated PSA. Impact: The findings underscore the limited utility of the 4Kscore in improving medium- to longer-term risk prediction over PSA, with potential benefits restricted to younger men with elevated PSA. 2025-11-27T14:07:35Z 2025-11-27T14:07:35Z 2025-08-22 2025-11-27T11:24:28Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.1158/1055-9965.EPI-24-1877 Cancer Epidemiology Biomarkers & Prevention, 2025, vol. 34, num. 11, p. 2058-2067 https://doi.org/10.1158/1055-9965.EPI-24-1877 cc-by (c) Smith-Byrne, Karl et al., 2025 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess American Association for Cancer Research (AACR) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))